Evidence map›Paper›PMID 38927057›Full record

ArticleBiomolecules2024

Application of Graph Models to the Identification of Transcriptomic Oncometabolic Pathways in Human Hepatocellular Carcinoma.

Sergio Barace, Eva Santamaría, Stefany Infante, Sara Arcelus, Jesus De La Fuente, Enrique Goñi, Ibon Tamayo, Idoia Ochoa, Miguel Sogbe, Bruno Sangro and 3 more

Abstract read
In one paragraph

Article in Biomolecules, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sergio BaraceDNA and RNA Medicine Division, Applied Medical Research Center (CIMA), University of Navarre, 31008 Pamplona, Spain.
Eva SantamaríaDNA and RNA Medicine Division, Applied Medical Research Center (CIMA), University of Navarre, 31008 Pamplona, Spain.ORCID 0000-0003-0629-6175
Stefany InfanteDNA and RNA Medicine Division, Applied Medical Research Center (CIMA), University of Navarre, 31008 Pamplona, Spain.ORCID 0000-0002-3067-233X
Sara ArcelusDNA and RNA Medicine Division, Applied Medical Research Center (CIMA), University of Navarre, 31008 Pamplona, Spain.
Jesus De La FuenteBioinformatics Platform, Applied Medical Research Center (CIMA), University of Navarre, 31008 Pamplona, Spain.
Enrique GoñiBioinformatics Platform, Applied Medical Research Center (CIMA), University of Navarre, 31008 Pamplona, Spain.ORCID 0000-0003-1792-4018
Ibon TamayoBioinformatics Platform, Applied Medical Research Center (CIMA), University of Navarre, 31008 Pamplona, Spain.
Idoia OchoaTecnun School of Engineering (TECNUN), University of Navarre, 31008 Pamplona, Spain.ORCID 0000-0003-1864-7868
Miguel SogbeLiver Unit, Tecnun School of Engineering (TECNUN), University of Navarre, 31008 Pamplona, Spain.ORCID 0000-0002-2846-7812
Bruno SangroCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBER-EHD), Av. Monforte de Lemos, 3-5. Pabellón 11, Planta 0, 28029 Madrid, Spain.ORCID 0000-0002-4177-6417
Mikel HernaezBioinformatics Platform, Applied Medical Research Center (CIMA), University of Navarre, 31008 Pamplona, Spain.
Matias A AvilaCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBER-EHD), Av. Monforte de Lemos, 3-5. Pabellón 11, Planta 0, 28029 Madrid, Spain.ORCID 0000-0001-6570-3557
Josepmaria ArgemiDNA and RNA Medicine Division, Applied Medical Research Center (CIMA), University of Navarre, 31008 Pamplona, Spain.ORCID 0000-0003-1696-7753

Funding

Agencia Estatal de Investigación PI20 01663Fundacion Echebano 2021-2022Ministerio de Ciencia, Innovación y Universidades PID2019-104878RB-100/AEI/10.13039/501100011033
6 · The paper itself

Abstract

Whole-tissue transcriptomic analyses have been helpful to characterize molecular subtypes of hepatocellular carcinoma (HCC). Metabolic subtypes of human HCC have been defined, yet whether these different metabolic classes are clinically relevant or derive in actionable cancer vulnerabilities is still an unanswered question. Publicly available gene sets or gene signatures have been used to infer functional changes through gene set enrichment methods. However, metabolism-related gene signatures are poorly co-expressed when applied to a biological context. Here, we apply a simple method to infer highly consistent signatures using graph-based statistics. Using the Cancer Genome Atlas Liver Hepatocellular cohort (LIHC), we describe the main metabolic clusters and their relationship with commonly used molecular classes, and with the presence of

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsTranscriptomebeta CateninCell Line, TumorGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMetabolic Networks and PathwaysMutationTumor Suppressor Protein p53beta CateninCTNNB1 protein, humanTumor Suppressor Protein p53gene set enrichment analysisgene set variation analysisgraphhepatocellular carcinomametabolismRNA sequencingsignature

Identifiers

PMID38927057
PMCPMC11201933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.